PMID- 17564346
OWN - NLM
STAT- MEDLINE
DCOM- 20070731
LR  - 20070613
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 3
IP  - 110
DP  - 2007 May 9
TI  - [Myasthenia gravis: treatments and remissions].
PG  - 1185-6, 1188-90
AB  - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction, 
      due to the binding of autoantibodies to the nicotinic acetylcholine receptor 
      (AChR), or more rarely to a muscle specific kinase (MuSK). It affects most of the 
      time young women and old patients, with a tendency toward increasing incidence 
      and prevalence. Clinical presentation, with fluctuating weakness of ocular, 
      facial and bulbar muscles has a wide range of severity. Evolution is 
      characterized by remissions and exacerbations. The goal of treatment is a 
      complete remission, which implies a sustained collaboration between the general 
      practitioner and the specialized centre and the use of symptomatic treatment 
      (anticholinesterasic) in association with immunomodulators/suppressors 
      (prednisone and azathioprine); although other treatments are available.
FAU - Dunand, Murielle
AU  - Dunand M
AD  - Unite nerf-muscle, Service de neurologie, CHUV, 1011 Lausanne. 
      murielle.dunand@chuv.ch
FAU - Lalive, Patrice H
AU  - Lalive PH
FAU - Vokatch, Natalia
AU  - Vokatch N
FAU - Kuntzer, Thierry
AU  - Kuntzer T
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Myasthenie grave, traitements et remissions.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
SB  - IM
MH  - Humans
MH  - Myasthenia Gravis/*diagnosis/*drug therapy
MH  - Remission Induction
RF  - 16
EDAT- 2007/06/15 09:00
MHDA- 2007/08/01 09:00
CRDT- 2007/06/15 09:00
PHST- 2007/06/15 09:00 [pubmed]
PHST- 2007/08/01 09:00 [medline]
PHST- 2007/06/15 09:00 [entrez]
PST - ppublish
SO  - Rev Med Suisse. 2007 May 9;3(110):1185-6, 1188-90.